Supplementary Figure S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Maria Coakley; Guillermo Villacampa; Prithika Sritharan; Claire Swift; Kathryn Dunne; Lucy Kilburn; Katie Goddard; Christodoulos Pipinikas; Patricia Rojas; Warren Emmett; Peter Hall; Catherine Harper‐Wynne; Tamas Hickish; Iain R. Macpherson; Alicia Okines; Andrew Wardley; Duncan Wheatley; Simon Waters; Carlo Palmieri; Matthew Winter; Rosalind J. Cutts; Isaac García-Murillas; Judith M. Bliss; Nicholas C. Turner

doi:10.1158/1078-0432.25232564

Abstract

Comparison of median lead time from ctDNA detection to relapse between dPCR and RaDaR assays using paired data in all individuals with relapse (n=40).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Coakley et al. (2024) studied this question.

synapsesocial.com/papers/68e78e41b6db643587700396 https://doi.org/10.1158/1078-0432.25232564

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers